Novo Nordisk to test key hemophilia drug in children in phase III

In a phase III trial, Novo Nordisk will investigate whether Mim8, which stems from a collaboration with Genmab, has potential to treat children with hemophilia A.

Photo: Tidsvilde Stine/Ritzau Scanpix

Pharmaceutical firm Novo Nordisk will not focus its attention exclusively on adults and adolescents when the pivotal testing phase of hemophilia drug Mim8 begins later this year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs